Valnevas Earnings Drop 35% And The Stock Still Underperforms

Valneva (VALN) reported fiscal 2025 Q4 earnings on March 17, 2026, with results underscoring a challenging operating environment. The company’s revenue fell 24.2% year-over-year to $38.51 million, while its net loss expanded to $50.02 million (or $0.29 per share), marking a 35.2% deterioration in profitability. The earnings report highlighted persistent operational pressures, with no guidance adjustments provided to address forward-looking expectations.

Revenue

The total revenue of Valneva decreased by 24.2% to $38.51 million in 2025 Q4, down from $50.78 million in 2024 Q4.

Earnings/Net Income

Valneva's losses deepened to $0.29 per share in 2025 Q4 from a loss of $0.23 per share in 2024 Q4 (27.9% wider loss). Meanwhile, the company's net loss widened to $-50.02 million in 2025 Q4, representing a 35.2% increase from the $-36.99 million loss recorded in 2024 Q4. The EPS and net loss figures indicate a deteriorating financial position, with no signs of near-term stabilization.

Price Action

The stock price of Valneva has edged up 2.71% during the latest trading day, has dropped 3.34% during the most recent full trading week, and has jumped 9.88% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Valneva (VALN) shares after a quarterly revenue drop on the financial report release date and holding for 30 days resulted in no return over the past three years. The strategy had a CAGR of 0.00% and an excess return of -49.27%, underperforming the benchmark by a significant margin. Additionally, the strategy had a maximum drawdown of 0.00% and volatility of 0.00%, indicating a risk-averse approach but failing to generate any returns.

CEO Commentary

Valneva’s CEO emphasized the need to address operational inefficiencies and cost structures in response to the 24.2% revenue decline and 35.2% increase in net losses. Leadership highlighted strategic priorities including optimizing R&D investments, strengthening commercial partnerships, and navigating regulatory hurdles. While acknowledging the current challenges, the CEO expressed cautious optimism about long-term growth potential, contingent on successful execution of cost-saving initiatives and leveraging key partnerships.

Guidance

The company provided no explicit forward-looking revenue or EPS guidance for 2026, reflecting uncertainty in its ability to reverse the current financial trajectory.

Additional News

Valneva secured an exclusive distribution agreement with Seqirus for IXIARO, IXCHIQ, and DUKORAL vaccines in Germany through 2028. The deal includes minimum purchase obligations and compliance requirements, with Valneva retaining IP and regulatory control. This partnership aims to bolster commercial reach and stabilize revenue streams amid operational challenges.